Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y2Z4
UPID:
SYYM_HUMAN
Alternative names:
Tyrosyl-tRNA synthetase
Alternative UPACC:
Q9Y2Z4; D3DUW8; Q9H817
Background:
Tyrosine--tRNA ligase, mitochondrial, also known as Tyrosyl-tRNA synthetase, plays a crucial role in protein synthesis. It catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction, involving the activation of tyrosine by ATP to form Tyr-AMP and its subsequent transfer to the acceptor end of tRNA(Tyr).
Therapeutic significance:
The protein is implicated in Myopathy with lactic acidosis and sideroblastic anemia 2, a rare disorder affecting skeletal muscle and bone marrow. This association highlights its potential as a target for therapeutic intervention in mitochondrial diseases.